Albireo announces $115 million royalty monetization agreement with sagard

Boston, sept. 22, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, entered into a royalty monetization agreement with sagard healthcare partners (“sagard”) for a total of $115 million upfront in return for a mid-single digit average royalty rate on bylvay global annual net revenues.
ALBO Ratings Summary
ALBO Quant Ranking